Waterland Private Equity Fund IV C.V., through its subsidiaries Enhold NV and Supply Holding B.V.
(“Waterland”), announces the successful placement of 8,363,865 existing ordinary shares (the “Shares”) of Arseus NV (“Arseus”), representing 26.67% of Arseus’ currently outstanding capital. Following strong demand, Waterland decided to upsize the transaction from 20.0% to the entire 26.67% stake it held in the company. The Shares have been placed at a price of €35.0 per share, resulting in gross cash proceeds of c. €292.7 million. Arseus will not receive any proceeds from the Offering.
The Shares were placed through an accelerated private placement to institutional investors inside and outside Belgium, and to qualified institutional buyers in the United States in reliance on Rule 144A.
Settlement will take place on Friday 11 April 2014.
J.P. Morgan Securities plc acted as Sole Global Coordinator and Joint Bookrunner, Petercam acted as Joint Bookrunner and KBC Securities acted as lead manager in connection with the Offering.
Waterland is an independent private equity investment group that supports entrepreneurs in realizing their growth ambitions. With substantial financial resources and committed industry expertise, Waterland enables its portfolio companies to achieve accelerated growth both organically and through acquisitions. Waterland is an active investor in the financial, strategic and operational sense. In the current dynamic business environment Waterland is a partner that provides entrepreneurs with a powerful position in the increasingly competitive international arena. Waterland currently has €2.5bn of capital under management, and holds offices in Bussum (NL), Antwerp (BE), Düsseldorf (DE), Munich (DE) and Warsaw (PL).
Arseus is a R&D scientific company delivering innovative solutions and concepts to professionals and institutions in the healthcare sector in 30 countries worldwide. Arseus is subdivided into three divisions: Fagron is global market leader in pharmaceutical compounding. Corilus develops and supplies unique integrated ICT solutions with substantial added value to medical specialists and is market leader in Belgium, France and the Netherlands. The Belgian company Arseus NV is located in Waregem, and is e Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.
This announcement is for general information only and does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.
This communication must not be published, released or distributed, directly or indirectly, in the United States, Canada, Japan, Australia, South Africa or any other jurisdiction where to do so would be prohibited by applicable law. These materials do not constitute an offer of or solicitation to purchase securities in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the United States Securities Act of 1933 (the “Securities Act”). The Shares mentioned herein have not been, and will not be, registered under the Securities Act. There will be no public offer of the Shares in the United States.
This communication is for distribution in member states of the European Economic Area only to persons falling within the meaning of Article 2(1)(e) of the 2003/71/CE directive as amended by Directive 2010/73/EU (the “Prospectus Directive”), and, where applicable, in accordance with Article 3(2) of the Prospectus Directive. In the United Kingdom, this document is being distributed only to, and is directed only at, investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) or who are high net worth entities falling within Article 49(2)(a) to (d) of the Order, and other persons to whom they may otherwise lawfully be communicated.